Northwest Biotherapeutics (NWBO) Net Equity Issued and Repurchased (2014 - 2026)

Northwest Biotherapeutics' Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 43.39% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $17.1 million, a 76.25% increase from a year earlier, with the FY2025 full-year figure at $19.3 million, up 135.57% from the prior year.
• Net Equity Issued and Repurchased advanced to $2.9 million in Q1 2026 per NWBO's latest filing, from $2.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $7.8 million in Q4 2022 and bottomed at -$1.8 million in Q4 2024.
• The 5-year median for Net Equity Issued and Repurchased is $3.5 million (2023), against an average of $3.7 million.
• Across the five-year window, Net Equity Issued and Repurchased plunged 152.75% in 2024 and jumped 1100.96% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $7.8 million in 2022, then sank by 55.81% to $3.4 million in 2023, then plunged by 152.75% to -$1.8 million in 2024, then surged by 211.33% to $2.0 million in 2025, then jumped by 43.92% to $2.9 million in 2026.
• Per Business Quant, the three latest NWBO Net Equity Issued and Repurchased figures stand at $2.9 million (Q1 2026), $2.0 million (Q4 2025), and $4.9 million (Q3 2025).